Trial intelligence / Profile preview

Orthokine for idiopathic trigeminal neuralgia

IRCT20190618043923N1Phase 2Completed

Sponsor
Tabriz University of Medical Sciences
Start
Aug 2019
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of autologous conditioned serum in Idiopathic Trigeminal Neuralgia (TN), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Pain intensity. Started Aug 2019; status: completed.

02

Drugs

autologous conditioned serum
03

Conditions

Idiopathic Trigeminal Neuralgia (TN)

Beyond the preview

Go deeper on IRCT20190618043923N1.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20190618043923N1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call